Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, GnRH agonist, and GnRH antagonist cycles

Min Hye Choi1, Sun Hee Lee2, Hye Ok Kim1, Sun Hwa Cha1, Jin Young Kim1, Kwang Moon Yang1, In Ok Song1, Mi Kyong Koong1, Inn Soo Kang1, Chan Woo Park1

Objective: We compared the assisted reproductive technology (ART) outcomes among infertile women with polycystic ovary syndrome (PCOS) treated with IVM, conventional IVF, GnRH agonist, and GnRH antagonist cycles.

Methods: The prospective study included a total of 67 cycles in 61 infertile women with PCOS. The women with PCOS were randomized into three IVF protocols: IVM/IVF with FSH and hCG priming with immature oocyte retrieval 38 hours later (group A, 14 cycles), GnRH agonist long protocol (group B, 14 cycles), and GnRH antagonist multi-dose flexible protocol (group C, 39 cycles). IVF outcomes, such as clinical pregnancy rate (CPR), implantation rate (IR), miscarriage rate (MR), and live birth rate (LBR), were compared among the three groups.

Results: Age, BMI, and basal FSH and LH levels did not differ among the three groups. The number of retrieved oocytes and 2 pronucleus embryos was significantly lower in group A compared with groups B and C. The CPR, IR, MR, and LBR per embryo transfer showed no differences among the three groups. There was no incidence of ovarian hyperstimulation syndrome in group A.

Conclusion: The IR, MR, and LBR in the IVM cycles were comparable to those of the GnRH agonist and GnRH antagonist cycles. The IVM protocol, FSH and hCG priming with oocyte retrieval 38 hours later, is an effective ART option that is comparable with conventional IVF for infertile women with PCOS.

Keywords: Polycystic ovary syndrome; In vitro maturation; GnRH antagonist; GnRH agonist; Assisted reproductive technology outcome

Introduction

Polycystic ovary syndrome (PCOS) is a common endocrinopathy. The prevalence of PCOS ranges from 3% to 7% in women of reproductive age [1] and may be as high as 20% among women with infertility [2]. The diagnostic criteria for PCOS were identified at a consensus meeting and are characterized by hyperandrogenism, the presence of typical ultrasound features of polycystic ovaries, and chronic anovulation in women without specific underlying disease of the adrenal or pituitary glands [3].

For infertile women with PCOS, clomiphene citrate (CC) is the first line of therapy. Some of these women are CC resistant and require other treatment, such as gonadotropin, ovarian drilling, or insulin sensitizing agents [4]. A proportion of PCOS women do not respond to these conventional treatments and ultimately require assisted reproductive technology (ART). Ovarian stimulation in women with
2. Controlled ovarian hyperstimulation

The participants underwent IVF treatment by the IVM/IVF with FSH and hCG priming protocol (group A, 14 cycles), the GnRH agonist long protocol (group B, 14 cycles), or the GnRH antagonist multi-dose flexible protocol (group C, 39 cycles).

1) The IVM/IVF with FSH and hCG priming protocol (group A) was used in 14 cycles. On days 2 to 3 of the menstrual cycle, the pelvic cavity was evaluated by transvaginal sonogram (TVS) and blood samples for assays of FSH, E2, and LH were obtained by venipuncture. The participants received 150 IU of recombinant FSH ( follitropin, Folliclute, LG, Ilsan, Korea) administered daily starting on day 2 to 3 until day 6-8 of the menstrual cycle. TVS was repeated on cycle day 6 or 8 to monitor the leading follicle. When the follicle size was greater than 12 mm and the thickness of the endometrium was greater than 6 mm, hCG (250 µg of choriogonadotropin-alfa, Ovidrel, Serono, Roma, Italy) was administered. 38 hours after hCG injection, immature oocyte retrieval was performed under TVS. The collected cumulus-oocyte complexes (COCs) were assessed for the presence or absence of a germinal vesicle or the first polar body by microscope. The retrieved immature oocytes were isolated and incubated in a 4-well dish containing IVM media (800 µL G2, VitroLife, Kungsbacka, Sweden) supplemented with 10% HSA (VitroLife), rFSH (75 mIU/mL, Gonal-F, Serono, Roma, Italy), rhCG (0.5 IU/mL, Ovidrel) and E2 (Sigma, St. Louis, MO, USA) at 37°C, 5% CO2 in humidified air. The mature oocytes were cultured for 4 hours and immature oocytes for up to 48 hours. After culture, the oocytes were denuded by hyaluronidase solution (0.1% hyaluronidase, Sigma, St. Louis, MO, USA), and their maturity was determined according to the presence of a first polar body by microscope. In all cases, the mature oocytes were inseminated by ICSI. After ICSI, normal fertilization was confirmed when two distinct pronuclei were present 16-18 hours later. If the in vitro matured oocytes produced good quality cleaved embryos, they were transferred transcervically. Luteal support was provided by 4 mg of estrogen valerate taken orally daily (Progynova, Schering-plough, Whitehouse Station, NJ, USA) beginning on the oocyte retrieval day and 50 mg progesterone in oil was also taken daily (Genefer progesterone, Watson Laboratories Inc., Corona, CA, USA) beginning on the day of ICSI up to gestational age 7 weeks.

2) In the GnRH agonist long protocol group (group B), pituitary suppression was initiated with GnRH agonist (0.5 mg buserelin acetate, Superfact, Sanofi-Aventis, Frankfurt, Germany or 0.1 mg leuprolide acetate, Lucrin, Abbott Lab, Chicago, IL, USA) from the mid-luteal phase of the previous cycle to the day of hCG administration. On day 2 to 3 of the menstrual cycle, the pelvic cavity was examined and blood samples were obtained by venipuncture for assays of FSH, E2, and LH.

3) In the GnRH antagonist multi-dose flexible protocol (group C),
stimulation using gonadotropin started on menstrual day 2 or 3, and GnRH antagonist (0.25 mg cetrorelix acetate, Cetrotide, Serono, Geneva, Switzerland or ganirelix acetate, Orgalutran, Schering-Plough) was administered when the follicles were more than 12 mm or serum E₂ concentrations were greater than 200 pg/mL.

The dosage of gonadotropin was determined by the age of the patient and the ovarian response of the previous cycle. The stimulation was monitored by assessments of follicle size and serum E₂ levels in groups B and C. In groups B and C, when a leading follicle was >12 mm in diameter, hCG (250 μg of choriogonadotropin-alfa, Ovidrel) was administered. TVS-guided oocyte retrieval was performed 36 hours after the hCG injection. The embryos were transferred into the uterine cavity on day 3 after oocyte retrieval. Pregnancy was determined by a serial serum β-hCG level of >5 mIU/mL 12 days after the oocyte retrieval. Clinical pregnancy was defined as the presence of a gestational sac by ultrasonography at approximately 5 weeks of pregnancy.

3. Statistical analysis

All analyses were performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). One-way analysis of variance was used for statistical analysis. Each variable is presented as the mean±SD. A p < 0.05 was considered statistically significant.

Results

Age, BMI, basal FSH and LH levels, and duration of infertility did not differ among the three groups (group A: 14 cycles, IVM/IVF with FSH and hCG priming protocol; group B: 14 cycles, GnRH agonist long protocol; group C: 39 cycles, GnRH antagonist multi-dose flexible protocol). The total doses of gonadotropin (group A: 1,008.3±326.3 vs. group B: 2,700.0±824.3 vs. group C: 1,657.7±669.8 IU; p = 0.001) and stimulation duration were significantly lower in group A than groups B and C (group A: 5.2±0.9 vs. group B: 11.6±2.0 vs. group C: 10.6±2.4 days; p = 0.00, respectively). Endometrial thickness on the day hCG was administered was significantly lower in group A than group B (Table 1).

The number of retrieved oocytes (group A: 9.9±5.1 vs. group B: 27.6±10.7 vs. group C: 19.4±11.1; p = 0.00) and the number of 2 pronucleus embryos (group A: 4.8±2.4 vs. group B: 16.4±6.5 vs. group C: 12.4±7.2; p = 0.00) were significantly lower in group A than groups B and C. In group A, the maturation rate was 63.1% and the fertilization rate was 75.5%, which was similar to groups B (75.6%) and C (77.8%). Embryo transfer was cancelled in two cycles of group B and in 10 cycles of group C. The implantation rate (group A: 24.4% vs. group B: 25.0% vs. group C: 23.3%) did not differ among the three groups. The CPR (group A: 53.8% vs. group B: 42.9% vs. group C: 51.7%), MR (group A: 14.3% vs. group B: 0% vs. group C: 10.3%), and LBR (group A: 38.5% vs. group B: 41.7% vs. group C: 34.5%) per embryo transfer did not differ among the three groups. In group B, 1 pregnancy had a 2nd trimester loss. In group C, 1 patient had an ectopic pregnancy. There was no incidence of OHSS in group A, and the differences from groups B and C were insignificant (group A: 0% vs. group B: 14.3% vs. group C: 17.9%) (Table 2).

Discussion

This is the first study to compare IVM outcomes with either a GnRH agonist or GnRH antagonist cycle in infertile women with PCOS. Furthermore, this is the only prospective study that has attempted to compare implantation and live birth rates across IVM and conventional IVF cycles, with no significant differences being seen in either rate.

In general, implantation and live birth rates of IVM embryos are still lower than those of conventional IVF embryos [13]. These findings may be explained by the fact that embryos derived from IVM have

---

**Table 1. Basal characteristics of the study population according to IVF protocol**

| Characteristic                          | IVM (group A) | GnRH agonist (group B) | GnRH antagonist (group C) |
|----------------------------------------|---------------|------------------------|--------------------------|
| No. of patients                         | 11            | 14                     | 36                       |
| No. of cycles                           | 14            | 14                     | 39                       |
| Age (yr)                                | 31.2±3.7      | 34.4±3.8               | 32.9±2.9                 |
| Duration of infertility (mo)            | 27.6±15.0     | 59.8±42.8              | 45.0±25.8                |
| Body mass index (kg/m²)                 | 24.6±4.9      | 23.6±4.0               | 23.3±4.3                 |
| Basal FSH (mIU/mL)                      | 6.49±1.85     | 7.09±2.32              | 7.43±2.15                |
| Basal LH (mIU/mL)                       | 3.62±2.39     | 5.41±4.55              | 4.66±3.09                |
| Duration of stimulation (day)           | 5.2±0.9<sup>a</sup> | 11.6±2.0 | 10.6±2.4               |
| Total dose of gonadotropin (IU)         | 1,008.3±326.3<sup>a</sup> | 2,700.0±824.3 | 1,656.7±669.77<sup>a</sup> |
| Endometrium thickness (mm)              | 9.2±1.5<sup>a</sup> | 11.8±2.3 | 10.5±1.89              |

Values are expressed as the mean±SD. p-value < 0.05, statistically significant.
<sup>a</sup>Group A vs. group B,
<sup>b</sup>group A vs. group C,
<sup>c</sup>group B vs. group C.
lower implantation potential than those derived from conventional IVF. As aneuploidy is a major cause of embryonic and fetal loss, it may be postulated that the higher incidence of chromosomal abnormalities in embryos derived from IVM oocytes may be a factor limiting the implantation potential of IVM embryos. Requena et al. [14] reported a higher aneuploidy rate (60%) in IVM embryos than in a control group (33%), in women with the risk of sex chromosome-linked diseases, based on FISH analysis of chromosomes 13, 15, 16, 18, 21, 22, X, and Y. It may be hypothesized that the higher incidence of chromosomal abnormalities, together with other cytoplasmic alterations due to the altered maturation of organelles in IVM, may account for the early cleavage arrest and low implantation rate. In the present study, we demonstrated an implantation rate of 24.4% with the FSH and hCG priming IVM protocol, which is comparable to that of conventional IVF cycles.

Although there have been conflicting reports on the clinical outcomes of FSH or hCG priming before IVM, advantages of early follicular phase FSH or hCG priming IVM cycles have been reported [10,11]. FSH priming in the early follicular phase may enhance follicular development and the maturational competence of immature oocytes. FSH receptors are exclusive to the granulosa cells of maturing follicles [15,16], which in turn are directly connected to the oocyte via gap junctions [17,18]. FSH effects on cumulus cells may therefore be directly transmitted to the oocyte via secondary messenger cAMP and one of its downstream target kinases [19,20]. Roberts et al. [21], using a mouse model, found that FSH accelerates oocyte maturation in COC undergoing IVM.

The application of hCG priming before immature oocyte retrieval has been an established IVM protocol since the first report of improved pregnancy rates after hCG priming [22,23]. In the present study, oocyte retrieval was performed 38 hours after hCG injection. The extension of the interval between hCG priming and oocyte retrieval to 38 hours promoted IVM, and prolonged hCG stimulation was positively correlated with the number of oocytes that matured in vitro [12].

When embryos were categorized based on the maturation time of the oocytes in IVM cycles, embryos derived from oocytes that matured 48 hours after retrieval had higher rates of chromosomal abnormalities than embryos derived from oocytes that matured in the first 24 hours after retrieval [24]. Possible interactions between FSH and hCG priming with immature oocyte retrieval 38 hours later and accelerated IVM may decrease the aneuploidy rate. In the present study, embryos derived from 24 hour mature oocytes may be preferentially transferred, which may increase the implantation potential as the aneuploidy rate is decreased with earlier IVM.

### Table 2. ART outcomes according to IVF protocol

|                        | IVM (group A) | GnRH-agonist (group B) | GnRH-antagonist (group C) |
|------------------------|--------------|------------------------|---------------------------|
| No. of cycles          | 14           | 14                     | 39                        |
| No. of retrieved oocytes | 9.9 ± 5.1a,b | 27.6 ± 10.7            | 19.4 ± 11.1               |
| No. of mature oocytes  | 1.3 ± 1.8a,b | 19.9 ± 8.5             | 14.8 ± 9.5                |
| No. of immature oocytes | 7.7 ± 5.3    | 4.2 ± 2.9              | 3.0 ± 4                   |
| Maturation rate (%)    | 63.1 ± 31.2a | 73.9 ± 17.9            | 76.9 ± 18.3               |
| No. of pronucleus embryos | 4.8 ± 2.4a   | 16.4 ± 6.5             | 12.4 ± 7.2                |
| Fertilization rate (%) | 75.0 ± 25.6  | 75.6 ± 14.5            | 77.8 ± 17.4               |
| No. of transferred embryos | 3.2 ± 0.6    | 3.3 ± 0.5              | 2.5 ± 0.9c                |
| No. of good quality embryos | 2.2 ± 2.3     | 4.3 ± 2.9              | 4.0 ± 2.2                 |
| CPR/attempt (%)        | 7/14 (50)    | 6/14 (42.9)            | 15/39 (38.5)              |
| CPR/ET (%)             | 7/13 (53.8)  | 6/12 (50)              | 15/29 (51.7)              |
| MR (%)                 | 2/14 (14.3)  | 0/14 (0)               | 4/39 (10.3)               |
| IR (%)                 | 10/41 (24.4) | 10/40 (25)             | 17/73 (23.3)              |
| LBR/attempt (%)        | 5/14 (35.7)  | 5/14 (35.7)            | 10/39 (25.6)              |
| LBR/ET (%)             | 5/13 (38.5)  | 5/12 (41.7)            | 10/29 (34.5)              |
| No. of OHSS (%)        | 0/14 (0)     | 2/14 (14.3)            | 7/39 (17.9)               |
| After singleton pregnancy |                    |                        |                          |
| hCG level on 12 day after OPU (mIU/mL) | 79.6 ± 64.3 | 49.8 ± 28.3 | 57.2 ± 49.3 |
| hCG level on 14 day after OPU (mIU/mL) | 173.5 ± 156.8 | 129.6 ± 98.0 | 149.2 ± 116.1 |

Values are presented as mean ± SD or number (%). p-value < 0.05, statistically significant.
ART, assisted reproductive technology; CPR, clinical pregnancy rate; ET, embryo transfer; MR, miscarriage rate; IR, implantation rate; LBR, live birth rate; OHSS, ovarian hyperstimulation syndrome; OPU, oocyte pick-up.

a Group A vs. group B, b Group A vs. group C, c Group B vs. group C.
mean numbers of transferred embryos between IVM and conventional IVF cycles. The initial β-hCG levels in successful IVM cycles were higher than either the GnRH agonist or GnRH antagonist cycles. It is likely that the higher β-hCG levels in the IVM group are responsible for the increased implantation potential, as there were no differences in the number of transferred embryos, as an initial high serum β-hCG level generally correlates favorably with pregnancy outcome.

In addition, the clinical abortion rate and live birth rate were not significantly different among the three groups in the present study. There are few reports of the clinical abortion rate in previous IVM studies, which ranged from 9% to 37% [25-27]. The clinical abortion rate after IVM tends to be higher than that of conventional IVF cycles. However, the reasons for the increased risk of clinical abortion after IVM remain unclear. In the present study, the clinical abortion rate in the IVM cycles was 14.3%, which was lower than the 25.3% seen in the largest study to address clinical abortion rates in 99 IVM cycles [28]. Although our sample was too small for a precise comparison, the lower clinical abortion rate we observed may be explained by reduced aneuploidy in the transferred embryos using the IVM protocol, with FSH and hCG priming with oocyte retrieval 38 hours later. The increased implantation potential with decreased clinical abortion with the FSH and hCG priming IVM protocol may have contributed to the live birth rates of 38.8%, which is comparable to either of the conventional IVF cycle types.

IVM provides the benefits of avoiding risks associated with OHSS, and there was no incidence of OHSS in this study. There was no difference in OHSS incidence between the GnRH agonist and GnRH antagonist cycles. A recent meta-analysis showed no significant differences in the incidence of severe OHSS with GnRH antagonist cycles as compared with GnRH agonist cycles [29]. A potential limitation associated with the present study are phenotypic differences between the infertile women with PCOS included in the sample, despite satisfying the Rotterdam criteria for inclusion in this study. In particular, women with PCOS who are at higher risk of OHSS may elect for IVM in place of conventional IVF.

In conclusion, in this study, the implantation and live birth rate in IVM were comparable to those of GnRH agonist or GnRH antagonist cycles. Although our sample is too small to make definitive conclusions, the present IVM protocol, FSH and hCG priming with immature oocyte retrieval 38 hours later, is an effective ART option comparable to conventional IVF for infertile women with PCOS. A large scale prospective study is warranted.

References

1. Knochenhauer ES, Key TJ, Khasar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83:3078-82.
2. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-74.
3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
4. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-22.
5. MacDougal MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993;8:233-7.
6. Griesinger G, Dietrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonist in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006;13:628-38.
7. Cha KY, Koo JJ, Ko JJ, Choi DH, Han SY, Yoon TK. Pregnancy after in vitro fertilization of human follicular oocytes collected from nonstimulated cycles, their culture in vitro and their transfer in a donor oocyte program. Fertil Steril 1991;55:109-13.
8. Buckett WM, Chian RC, Holzer H, Dean N, Usher R, Tan SL. Obstetric outcomes and congenital abnormalities after in vitro maturation, in vitro fertilization, and intracytoplasmic sperm injection. Obstet Gynecol 2007;110:885-91.
9. Siristatidis CS, Maheshwari A, Bhattacharya S. In vitro maturation in sub fertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev 2009; (1):CD006606.
10. Son WY, Yoon SH, Lim JH. Effect of gonadotrophin priming on in-vitro maturation of oocytes collected from women at risk of OHSS. Reprod Biomed Online 2006;13:340-8.
11. Son WY, Chung JT, Demirtas E, Holzer H, Sylvestre C, Buckett W, et al. Comparison of in-vitro maturation cycles with and without in-vivo matured oocytes retrieved. Reprod Biomed Online 2008;17:59-67.
12. Son WY, Chung JT, Chian RC, Herrera B, Demirtas E, Elizur S, et al. A 38 h interval between hCG priming and oocyte retrieval increases in vivo and in vitro oocyte maturation rate in programmed IVM cycles. Hum Reprod 2008;23:2010-6.
13. Son WY, Chung JT, Herrera B, Dean N, Demirtas E, Holzer H, et al. Selection of the optimal day for oocyte retrieval based on the di-
ameter of the dominant follicle in hCG-primed in vitro maturation cycles. Hum Reprod 2008;23:2680-5.

14. Requena A, Bronet F, Guillén A, Agudo D, Bou C, García-Velasco JA. The impact of in-vitro maturation of oocytes on aneuploidy rate. Reprod Biomed Online 2009;18:777-83.

15. Camp TA, Rahal JO, Mayo KE. Cellular localization and hormonal regulation of follicle-stimulating hormone and luteinizing hormone receptor messenger RNAs in the rat ovary. Mol Endocrinol 1991;5:1405-17.

16. O’Shaughnessy PJ, Dudley K, Rajapaksha WR. Expression of follicle stimulating hormone-receptor mRNA during gonadal development. Mol Cell Endocrinol 1996;125:169-75.

17. Albertini DF, Anderson E. The appearance and structure of intercellular connections during the ontogeny of the rabbit ovarian follicle with particular reference to gap junctions. J Cell Biol 1974;63:234-50.

18. Anderson E, Albertini DF. Gap junctions between the oocyte and companion follicle cells in the mammalian ovary. J Cell Biol 1976;71:680-6.

19. Richards JS. New signaling pathways for hormones and cyclic adenosine 3',5'-monophosphate action in endocrine cells. Mol Endocrinol 2001;15:209-18.

20. Gonzalez-Robayna IJ, Falender AE, Ochsner S, Firestone GL, Richards JS. Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-Induced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells. Mol Endocrinol 2000;14:1283-300.

21. Roberts R, Stark J, Iatropoulou A, Becker DL, Franks S, Hardy K. Energy substrate metabolism of mouse cumulus-oocyte complexes: response to follicle-stimulating hormone is mediated by the phosphatidylinositol 3-kinase pathway and is associated with oocyte maturation. Biol Reprod 2004;71:199-209.

22. Chian RC, Gülekli B, Buckett WM, Tan SL. Priming with human chorionic gonadotropin before retrieval of immature oocytes in women with infertility due to the polycystic ovary syndrome. N Engl J Med 1999;341:1624-6.

23. Chian RC, Buckett WM, Tulandi T, Tan SL. Prospective randomized study of human chorionic gonadotrophin priming before immature oocyte retrieval from unstimulated women with polycystic ovarian syndrome. Hum Reprod 2000;15:165-70.

24. Zhang XY, Awa B, Son WY, Buckett WM, Tan SL, Ao A. Chromosome abnormality rates in human embryos obtained from in-vitro maturation and IVF treatment cycles. Reprod Biomed Online 2010;21:552-9.

25. Cha KY, Chung HM, Lee DR, Kwon H, Chung MK, Park LS, et al. Obstetric outcome of patients with polycystic ovarian syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer. Fertil Steril 2005;83:1461-5.

26. Le Du A, Kadoch U, Bourcigaux N, Doumerc S, Bourrier MC, Chevalier N, et al. In vitro oocyte maturation for the treatment of infertility associated with polycystic ovarian syndrome: the French experience. Hum Reprod 2005;20:420-4.

27. Lin YH, Hwang JL. In vitro maturation of human oocytes. Taiwan J Obstet Gynecol 2006;45:95-9.

28. Buckett WM, Chian RC, Dean NL, Sylvestre C, Holzer HE, Tan SL. Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection. Fertil Steril 2008;90:546-50.

29. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012;24:6-22.